Abstract
A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus (COVID-19). With the rapid increase of infected patients and deaths, it is vital to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patients; some of the them will develop acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, and even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs used during the outbreak.
Keywords: Mesenchymal stem cells, coronavirus disease 2019, acute respiratory distress syndrome, dysfunction, cytokine, syndrome.
Current Stem Cell Research & Therapy
Title:Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential
Volume: 16 Issue: 2
Author(s): Jing Xiong, Lei Bao, Hongbo Qi, Zhichun Feng*Yuan Shi*
Affiliation:
- Bayi Children’s Hospital, The Seventh Medical Center, PLA General Hospital, Beijing,China
- Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation base of Child development and Critical Disorders; Children’s Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014,China
Keywords: Mesenchymal stem cells, coronavirus disease 2019, acute respiratory distress syndrome, dysfunction, cytokine, syndrome.
Abstract: A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus (COVID-19). With the rapid increase of infected patients and deaths, it is vital to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patients; some of the them will develop acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, and even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs used during the outbreak.
Export Options
About this article
Cite this article as:
Xiong Jing , Bao Lei , Qi Hongbo , Feng Zhichun *, Shi Yuan *, Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential, Current Stem Cell Research & Therapy 2021; 16 (2) . https://dx.doi.org/10.2174/1574888X15666200601152832
DOI https://dx.doi.org/10.2174/1574888X15666200601152832 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis
Current Neuropharmacology Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Current Medicinal Chemistry Isolation and Biological Evaluation of Novel Tetracosahexaene Hexamethyl, an Acyclic Triterpenoids Derivatives and Antioxidant from Justicia adhatoda
Combinatorial Chemistry & High Throughput Screening Hydrogen Sulfide in Physiological and Pathological Mechanisms in Brain
CNS & Neurological Disorders - Drug Targets Inflammation in Atherosclerosis: A New Therapeutic Target
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Computational Simulations as Preformulation Perspective for the Delivery of NSAIDs Using β-Cyclodextrin
Letters in Drug Design & Discovery Editorial [Hot Topic: Akt Pathway in Oncogenesis and as a Target for Anti-Cancer Therapy (Guest Editor: Jin Q. Cheng) ]
Current Cancer Drug Targets <i>Nigella Sativa</i> (Black seeds) – Potential Herb to Help Weight Loss
Current Traditional Medicine In vitro Effects of Polyphenols on the Peripheral Immune Responses in Nickel-sensitized Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Dibenzylbutyrolactone Lignans – A Review of Their Structural Diversity, Biosynthesis, Occurrence, Identification and Importance
Mini-Reviews in Medicinal Chemistry Oxindole Derivatives: Synthesis and Antiglycation Activity
Medicinal Chemistry Visceral Leishmaniasis: Advances in Treatment
Recent Patents on Anti-Infective Drug Discovery Protective Effects of <i>Antrodia cinnamomea</i> and Its Constituent Compound Dehydroeburicoic Acid 32 Against Alcoholic Fatty Liver Disease
Current Molecular Pharmacology Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered
Current Medicinal Chemistry Kallikrein-Kinin System Mediated Inflammation in Alzheimers Disease In Vivo
Current Alzheimer Research Death Receptor Activation-Induced Hepatocyte Apoptosis and Liver Injury
Current Molecular Medicine A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) RNAi of cat-2, a Putative Tyrosine Hydroxylase, Increases Alpha Synuclein Aggregation and Associated Effects in Transgenic C. elegans
CNS & Neurological Disorders - Drug Targets